(Q24194019)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24919460%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

meta-analysis

0 references

title

Trastuzumab-containing regimens for metastatic breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24919460%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

main subject

metastatic breast cancer

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24919460%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Sara Balduzzi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24919460%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Valentina Guarneri

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24919460%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Lorenzo Moja

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24919460%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Stefania Mantarro

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24919460%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Ludovica Tagliabue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24919460%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Vanna Pistotti

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24919460%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

publication date

12 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24919460%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

20 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24919460%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24919460%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

CD006242

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24919460%20AND%20SRC:MED&resulttype=core&format=json

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

20 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Trastuzumab Improves the Efficacy of Chemotherapy in Breast Cancer Treatment beyond Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a r

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Evaluating non-randomised intervention studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic ana

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

21 January 2018

Disappointing biotech

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Metastatic behavior of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Trastuzumab containing regimens for early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

First-line Herceptin monotherapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006242.PUB2

21 January 2018

1 reference

12 December 2020

Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?

1 reference

12 December 2020

Cardiac dysfunction in the trastuzumab clinical trials experience

1 reference

12 December 2020

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

12 December 2020

Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: a systematic review of published studies.

1 reference

12 December 2020

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer

1 reference

12 December 2020

Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer

1 reference

12 December 2020

Recent trends in epidemiology of brain metastases: an overview.

1 reference

12 December 2020

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

12 December 2020

10.1002/14651858.CD006242.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24919460%20AND%20SRC:MED&resulttype=core&format=json

release_ddfntyz7nrdazf3rhqivc7bmuy

20 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ddfntyz7nrdazf3rhqivc7bmuy

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24919460%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference